Clinical Trials

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

557 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03901339 2024-10-21

TROPiCS-02

543 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT03786094 2023-11-01

FORTRESS

Phase 3 Terminated

432 enrolled 13 charts

Breast Neoplasms

NCT00879086 2023-06-22

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

104 enrolled 16 charts

Breast Neoplasms, Neoplasms

NCT01104155 2023-06-22

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

123 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01126736 2023-06-22

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

98 enrolled 15 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01268150 2023-06-22

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

56 enrolled 10 charts

Breast Neoplasms

NCT01269346 2023-06-22

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

52 enrolled 9 charts

Breast Neoplasms

NCT01327885 2023-06-22

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

452 enrolled 11 charts

NCT01439282 2023-06-22

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

77 enrolled 9 charts

Breast Neoplasms

NCT02915744 2023-04-14

ATTAIN

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT03441360 2022-10-05

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

23 enrolled 14 charts

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

NCT03245450 2022-06-28

Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

40 enrolled 30 charts

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

NCT02574455 2022-06-15

ASCENT

529 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT02513472 2022-05-05

ENHANCE-1

258 enrolled 18 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01126749 2022-02-28

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Phase 1/2 Terminated

92 enrolled 15 charts

Genitourinary

Urinary Bladder Neoplasms

NCT02555657 2021-12-10

KEYNOTE-119

622 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT01323530 2021-01-11

A Confirmation Study of Eribulin in Combination With Capecitabine

76 enrolled 24 charts

Breast Neoplasms

NCT02753595 2020-07-13

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Phase 1/2 Terminated

25 enrolled 9 charts

Breast Neoplasms

NCT00337103 2020-06-18

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

1,276 enrolled 22 charts

Breast Neoplasms

NCT00388726 2020-01-07

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

762 enrolled 12 charts

Breast Neoplasms

NCT01328249 2019-08-20

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

81 enrolled 9 charts

Breast Neoplasms

NCT01945710 2019-07-23

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

62 enrolled 28 charts

Neoplasms

NCT02171260 2019-01-15

BOLD 113

23 enrolled 22 charts

Lymphoid

Lymphoma, Neoplasms

NCT02481050 2018-11-15

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

58 enrolled 14 charts

Breast Neoplasms

NCT00413192 2017-04-26

E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

128 enrolled 16 charts

NCT01427933 2017-02-06

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

141 enrolled 15 charts

Breast Neoplasms

NCT01961544 2016-10-07

ESKIMO

Phase 4 Completed

101 enrolled 6 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00246090 2014-07-14

A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

298 enrolled 8 charts

Breast Neoplasms

NCT00278993 2014-07-14

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

108 enrolled 11 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01000376 2013-09-23

Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors

12 enrolled 9 charts

Neoplasms

NCT01142661 2013-09-20

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

Phase NA Completed

9 enrolled 8 charts

Breast Neoplasms

NCT00965523 2013-08-15

Study of E7389 for Advanced or Metastatic Breast Cancer

81 enrolled 7 charts

Breast Neoplasms, Neoplasms

NCT00097721 2013-04-22

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

104 enrolled 12 charts

Breast Neoplasms

NCT00268905 2013-02-12

A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors

64 enrolled 11 charts

Neoplasms

NCT01106248 2012-04-13

QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors

26 enrolled 9 charts

Neoplasms

NCT00069277 2012-04-11

Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

21 enrolled 7 charts

Neoplasms

NCT00100932 2012-03-27

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

106 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00706095 2012-03-27

Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System

18 enrolled 10 charts

Neoplasms

NCT00908908 2012-03-09

A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors

6 enrolled 7 charts

Other solid neoplasm

Advanced Solid Tumors

NCT00069264 2011-12-20

Study of E7389 in Patients With Advanced Solid Tumors

33 enrolled 8 charts